EMA Head: Conditional authorization for Gilead’s Remdesivir in EU to be granted in coming days

Speaking at a hearing in the European Union (EU) Parliament in Brussels on Monday, the European Medicines Agency (EMA) Head Guido Rasi said an initial authorization for US pharmaceutical company Gilead Sciences’ Remdesivir as a coronavirus treatment could be granted in coming days, per Reuters.

more to come ...